Medicus Pharma’s (MDCX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report published on Thursday morning,Benzinga reports. The brokerage currently has a $27.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Medicus Pharma Trading Up 1.8%

Shares of NASDAQ:MDCX opened at $0.51 on Thursday. The firm has a market capitalization of $13.00 million, a PE ratio of -0.24 and a beta of -1.58. Medicus Pharma has a 1-year low of $0.37 and a 1-year high of $8.94. The business’s 50 day moving average is $1.07 and its 200-day moving average is $1.76.

Institutional Investors Weigh In On Medicus Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new position in shares of Medicus Pharma in the 4th quarter worth approximately $2,771,000. Yorkville Advisors Global LP acquired a new stake in Medicus Pharma in the 3rd quarter valued at $532,000. Jane Street Group LLC acquired a new stake in Medicus Pharma in the 4th quarter valued at $92,000. HRT Financial LP bought a new stake in Medicus Pharma in the fourth quarter valued at $42,000. Finally, Wilmington Savings Fund Society FSB grew its position in Medicus Pharma by 100.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after acquiring an additional 25,622 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.